DMEMEDS shared post via Reuters: FDA panel recommends more clinical data on AstraZeneca drug

WASHINGTON (Reuters) - An advisory panel to the U.S. Food and Drug Administration recommended on Wednesday that AstraZeneca Plc be required to submit further clinical data before its experimental ovarian cancer drug is approved. [Category: healthNews] http://feeds.reuters.com/~r/reuters/healthNews/~3/x3cfOJuqhrI/story01.htm

Read More